OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SONME55

Sonmez Filament Sentetik Iplik ve Elyaf Sanayi AS

Specialty ChemicalsVerified

Sonmez Filament maintains a strong liquidity position with a current ratio of 13.09, indicating a high ability to meet short-term obligations, supported by 96.5 million TRY in cash and equivalents. The company has no long-term debt, and its debt-to-equity ratio is 0.0, reflecting a conservative capital structure. Despite strong operating cash flow of 100.4 million TRY, the company reported a net loss of 225.0 million TRY, resulting in a negative return on equity of -5.17% and a return on assets of -4.53%. These figures fall significantly below the typical performance metrics for the Specialty Chemicals industry, indicating poor profitability and asset utilization. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and customer concentration risks. Looking ahead, the company is expected to face a challenging growth environment, with no clear indicators of revenue recovery in the near term. The free cash flow is negative at -223.3 million TRY, and capital expenditures are minimal at -128,740 TRY, suggesting limited investment in future growth. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. However, the significant net loss and negative returns suggest operational and financial risks that could impact long-term stability. No dilution is expected in the near term, as shares outstanding remain unchanged between basic and diluted measures. Recent filings and transcripts do not provide additional insights into the company's strategic direction or operational performance. The absence of detailed disclosures limits the ability to assess management's response to current challenges.

30-day price · SONME-6.90 (-4.9%)
Low$121.00High$155.10Close$133.50As of25 May, 00:00 UTC
Profile
CompanySonmez Filament Sentetik Iplik ve Elyaf Sanayi AS
TickerSONME.IS
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustrySpecialty Chemicals
AI analysis

Business. Sonmez Filament Sentetik Iplik ve Elyaf Sanayi AS produces synthetic fibers and filaments, primarily serving the textile and apparel industries, and generates revenue through the sale of these materials.

Classification. The company is classified under the Basic Materials economic sector, Chemicals business sector, and Specialty Chemicals industry, with a confidence level of 0.92 based on verified market data.

Sonmez Filament maintains a strong liquidity position with a current ratio of 13.09, indicating a high ability to meet short-term obligations, supported by 96.5 million TRY in cash and equivalents. The company has no long-term debt, and its debt-to-equity ratio is 0.0, reflecting a conservative capital structure. Despite strong operating cash flow of 100.4 million TRY, the company reported a net loss of 225.0 million TRY, resulting in a negative return on equity of -5.17% and a return on assets of -4.53%. These figures fall significantly below the typical performance metrics for the Specialty Chemicals industry, indicating poor profitability and asset utilization. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and customer concentration risks. Looking ahead, the company is expected to face a challenging growth environment, with no clear indicators of revenue recovery in the near term. The free cash flow is negative at -223.3 million TRY, and capital expenditures are minimal at -128,740 TRY, suggesting limited investment in future growth. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. However, the significant net loss and negative returns suggest operational and financial risks that could impact long-term stability. No dilution is expected in the near term, as shares outstanding remain unchanged between basic and diluted measures. Recent filings and transcripts do not provide additional insights into the company's strategic direction or operational performance. The absence of detailed disclosures limits the ability to assess management's response to current challenges.
Key takeaways
  • The company has a strong liquidity position with a high current ratio and no long-term debt.
  • Despite strong operating cash flow, the company is unprofitable with negative returns on equity and assets.
  • Revenue and operations are concentrated in a single segment, increasing exposure to market and customer risks.
  • No immediate liquidity or dilution risks are present, but the company's financial performance raises concerns about long-term sustainability.
  • Minimal capital expenditures suggest limited investment in future growth.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTRY
Revenue$60.6M
Gross profit
Operating income$40.7M
Net income-$225.0M
R&D
SG&A
D&A
SBC
Operating cash flow$100.4M
CapEx-$128.7k
Free cash flow-$223.3M
Total assets$4.97B
Total liabilities$616.7M
Total equity$4.36B
Cash & equivalents$96.5M
Long-term debt$0.00
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$4.36B
Net cash$96.5M
Current ratio13.1
Debt/Equity0.0
ROA-4.5%
ROE-5.2%
Cash conversion-45.0%
CapEx/Revenue-0.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricSONMEActivity
Op margin67.2%5.5% medp25 -0.0% · p75 10.8%top quartile
Net margin-371.3%4.1% medp25 0.1% · p75 8.8%bottom quartile
Gross margin20.5% medp25 12.4% · p75 29.7%
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-0.2%-6.2% medp25 -13.4% · p75 -2.6%top quartile
Debt / equity0.0%37.1% medp25 10.3% · p75 82.0%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-24 18:15 UTC#cb38f752
Market quoteclose TRY 133.00 · shares 0.07B diluted
no public URL
2026-05-24 18:15 UTC#de8f35a1
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 12:44 UTCJob: 05c80108